Iohexol

Iohexol
Systematic (IUPAC) name

1-N,3-N-bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	Intrathecal, intravascular, oral, intracavital, rectal
Legal status	℞ (Prescription only)
Pharmacokinetic data
Protein binding	Low
Metabolism	Nil
Biological half-life	Variable
Excretion	Renal, unchanged
Identifiers
CAS Number	66108-95-0^Y
ATC code	V08AB02 (WHO)
PubChem	CID 3730
DrugBank	DB01362^Y
ChemSpider	3599^Y
UNII	4419T9MX03^Y
KEGG	D01817^Y
ChEBI	CHEBI:31709^Y
ChEMBL	CHEMBL1200455^N
Synonyms	5-[N-(2,3-Dihydroxypropyl)acetamido]-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide
Chemical data
Formula	C₁₉H₂₆I₃N₃O₉
Molar mass	821.138 g/mol
SMILES O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCC(O)CO)C(=O)NCC(O)CO)CC(O)CO)C
InChI InChI=1S/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34)^Y Key:NTHXOOBQLCIOLC-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)

Iohexol is a contrast agent, sold under the trade names Omnipaque and Exypaque; this compound is also sold as a density gradient medium under the names Accudenz, Histodenz and Nycodenz.^[1]^[2] It is available in various concentrations, from 140 to 350 milligrams of iodine per milliliter. Omnipaque 350 is commonly used as a contrast agent during coronary angiography.

The osmolality of iohexol ranges from 322 mOsm/kg—approximately 1.1 times that of blood plasma—to 844 mOsm/kg, almost three times that of blood.^[3] Despite this difference, iohexol is still considered a low-osmolality contrast agent; the osmolality of older agents, such as diatrizoate, may be more than twice as high.^[4]

References

↑ "HistoDenz (D2158)", product information sheet, Sigma-Aldrich. Accessed on line Nov. 19, 2015.
↑ "Nycodenz®: A universal density gradient medium", Axis-Shield Density Gradient Media. Accessed on line Nov. 19, 2015.
↑ GE Healthcare (May 2006). "Omnipaque (Iohexol) injection. Product label". DailyMed. U.S. National Library of Medicine. Retrieved 2007-03-28.
↑ Amersham Health (April 2006). "Hypaque (Diatrizoate Meglumine and Diatrizoate Sodium) injection, solution. Product label". DailyMed. U.S. National Library of Medicine. Retrieved 2007-03-29.

External links

Omnipaque (Iohexol) injection, solution

Contrast media (V08)

X-ray and CT

Iodinated,
Water soluble

Nephrotropic, high osmolar	Diatrizoic acid^# Metrizoic acid Iodamide Iotalamic acid Ioxitalamic acid Ioglicic acid Acetrizoic acid Iocarmic acid Methiodal Diodone

Nephrotropic, low osmolar	Metrizamide Iohexol^# Ioxaglic acid Iopamidol Iopromide Iotrolan Ioversol Iopentol Iodixanol Iomeprol Iobitridol Ioxilan

Hepatotropic	Iodoxamic acid Iotroxic acid Ioglycamic acid Adipiodone Iobenzamic acid Iopanoic acid Iocetamic acid Sodium iopodate Tyropanoic acid Calcium iopodate

Iodinated,
Water insoluble

Non-iodinated

Barium sulfate^#

MRI

Paramagnetic	Gadolinium-based: Gadobenic acid Gadobutrol Gadodiamide Gadofosveset Gadolinium Gadopentetic acid Gadoteric acid Gadoteridol Gadoversetamide Gadoxetic acid Other: Ferric ammonium citrate Mangafodipir

Superparamagnetic	Ferumoxsil Ferristene Iron oxide, nanoparticles

Other	Perflubron

Ultrasound

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.